Jun proto-oncogene, AP-1 transcription factor subunit
Jun proto-oncogene, AP-1 transcription factor subunit (commonly JUN) encodes a major component of the activator protein-1 (AP-1) transcription factor complex.
Jun proto-oncogene, AP-1 transcription factor subunit (commonly JUN) encodes a major component of the activator protein-1 (AP-1) transcription factor complex. JUN is a nuclear transcriptional regulator that integrates signals from multiple upstream pathways, including MAPK signaling, PI3K/Akt signaling pathway, inflammatory cascades, and stress responses. By forming homo- or heterodimers with other AP-1 family proteins, JUN helps control gene expression programs involved in cell proliferation, differentiation, survival, migration, and inflammatory activation.
Biomedically, JUN is widely studied as a proto-oncogene because AP-1 activity can support tumor growth, invasion, and adaptation to stress. At the same time, JUN is also implicated in nonmalignant disease processes such as inflammation, fibrosis, and vascular remodeling. Its activity is often assessed in relation to downstream transcriptional programs involving MYC proto-oncogene (MYC), signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa B, BCL2 apoptosis regulator, Interleukin-1β (IL-1β), and matrix-remodeling genes such as MMP9, reflecting its role as a central signaling node rather than a disease-specific effector.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
9 papers study jun proto-oncogene, ap-1 transcription factor subunit directly. Those 9 are one subject: AP-1 Disease Biology. Cancer signaling, inflammatory disease, neurodegeneration and computational drug discovery appear without a shared mechanism or clinical endpoint. The cluster offers no clear direction beyond scattered AP-1-related biology. No way of splitting those 9 scores better than chance.
Recent Findings on Jun proto-oncogene, AP-1 transcription factor subunit
Inflammatory and Cancer Signaling: JUN/AP-1 transcriptional activity links tumor proliferation, invasion, immune suppression, and inflammatory disease. In colorectal cancer, 7SK selectively activates the JUN transcriptional network while reducing global transcriptional entropy, thereby stabilizing an immunosuppressive microenvironment and promoting immune escape 42709882Sep. CD46 activates AP-1 through p38 MAPK and PI3K/AKT signaling, increasing MMP9 expression and cancer-cell migration and invasion 42049325Apr. In IgA nephropathy, JUN forms part of a six-gene pyroptosis-related hub with high diagnostic accuracy and associations with immune-cell infiltration, inflammation, and cell migration 42135973May. These studies support JUN/AP-1 as a biomarker and therapeutic axis, but they examine distinct mechanisms and disease contexts.
Microbiota–Immune Drug Targets: Gut microbiota-derived metabolites and repurposed drugs converge on host immune-inflammatory networks that include JUN. In Alzheimer disease, JUN and FOS occupy central positions alongside IL6, NFKB1, IL1B, CXCL8, and PPARG, with links to NOD-like receptor, TNF, NF-κB, and MAPK signaling 42406869Jul. A cross-ecosystem network analysis likewise identifies JUN as a conserved host regulator connecting microbial perturbations with inflammatory and cardiometabolic pathways 42249966Jun. Molecular docking prioritizes several metabolites, while network ranking highlights indomethacin, ibuprofen, dexibuprofen, mesalazine, and cannabidiol as repurposing candidates. These computational results provide hypothesis-generating targets for host-directed treatment, but the metabolite associations and therapeutic effects require experimental validation 42406869Jul42249966Jun.
JUN/AP-1 also appears in heatstroke injury, early colorectal tumorigenesis, and nutraceutical target networks. Heatstroke alters Jun expression in the hypothalamus alongside endoplasmic reticulum protein processing, MAPK signaling, and apoptosis, with Hspb1 and Dnaja1 identified in the same multi-omics analysis 42412186Jul. In APC/TP53 double-knockout human colon organoids, FOS/JUN-driven chromatin remodeling increases KIT expression, activating MAPK and Wnt signaling to sustain proliferation and tumorigenesis 42401564Jul. Vernolac network analysis identifies JUN among cancer-related hub nodes, while in vitro assays show selective antiproliferative activity against several cancer cell lines 42384725Jul. These findings extend JUN-related signaling across stress responses and cancer models, while nutraceutical mechanisms remain supported mainly by network analysis, molecular docking, and preclinical assays.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-07-06. Last written: 2026-09-10 by GPT. Drafted by language models from published abstracts; not medical advice.